Semaglutide
medicationA GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
Eloralintide is a peptide that is research only, not approved for human use in the US.
Also known as LY3841136
Eloralintide is designed to act through amylin receptors involved in appetite and fullness. It is an early clinical-development medicine, not an approved product available from research vendors.

Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it. Not FDA-approved. Access for people is limited to authorized clinical trials.
As of September 28, 2026.
Early human trials are underway; evidence is not yet sufficient for an approved label or routine clinical use.
These save with the compound when you add it to My Journal, so they’re on the printout for your visit.
Eloralintide is not approved for human use, so DiscoverMedica links to no seller.
We don’t link to sellers of research-only compounds. Products sold “for research use only” are not made for people and are not held to pharmaceutical quality standards.
Educational information only, not medical advice. It does not replace a conversation with a licensed clinician.
A GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
A weekly GIP and GLP-1 medication approved for weight management, sleep apnea and type 2 diabetes.
An older, daily GLP-1 injection for weight management and diabetes, now available as a generic.
A cheap, decades-old diabetes pill that some people ask about for weight and healthy aging.